ArticleFrontiers in cell and developmental biology2026
Assessment of Vedolizumab and UC-MSC interaction and therapeutic potential in acute graft-versus-host-disease.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute graft-versus-host disease (aGvHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation, characterized by donor T-cell-mediated immune responses against the host. This condition significantly impacts patient quality of life, and it is associated with mortality, particularly when the gastrointestinal tract is affected. This study investigated the potential therapeutic synergy between umbilical cord-derived mesenchymal stromal cells (UC-MSCs), known for their immunomodulatory potential, and Vedolizumab (VDZ), a gut-specific α4β7 integrin antagonist that prevents lymphocyte trafficking to intestinal tissues. Our results demonstrate that UC-MSCs maintain an unaltered immunophenotype and low α4β7 expression in the presence of VDZ, even under inflammatory conditions. Moreover, VDZ exposure did not modify UC-MSC immunomodulatory functions, IDO expression, or susceptibility to peripheral blood mononuclear cell-mediated lysis. In an NSG mouse model of aGvHD, single-agent therapies showed limited effects on survival, whereas combined VDZ and UC-MSCs highlighted the critical importance of optimizing administration windows and dosing schedules. Although no clear synergistic therapeutic benefits were observed in this model, the absence of toxicity or mutual inhibition establishes a favorable safety profile for the combination of VDZ and UC-MSCs as rescue therapy for steroid-refractory aGvHD. These findings also provide a rationale for exploring this combination in a prophylactic setting, preventing gastrointestinal aGvHD by limiting early lymphocyte trafficking while preserving systemic immune regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.